Search Results - "Wiele, A.J."

678P Cytoreductive nephrectomy (CN) for patients with metastatic sarcomatoid and/or rhabdoid (S/R) renal cell carcinoma (RCC) treated with immune checkpoint inhibitors (ICI) by Hahn, A.W., Viscuse, P.V., Pieretti, A., Wiele, A.J., Jonasch, E., Gao, J., Zurita, A.J., Shah, A.Y., Campbell, M.T., Sharma, P., Wood, C.G., Tannir, N.M., Karam, J.A., Msaouel, P.

Get full text

Lenvatinib (Len) alone or in combination with everolimus (Eve) in heavily pretreated patients (pts) with metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitors (ICI) and VEGFR-targeted therapies: A single-institution experience by Wiele, A.J., Ross, J., Chahoud, J., Lim, Z., Xiao, L., Campbell, M.T., Shah, A.Y., Zurita Saavedra, A., Jonasch, E., Tannir, N.M.

Get full text

964P - Lenvatinib (Len) alone or in combination with everolimus (Eve) in heavily pretreated patients (pts) with metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitors (ICI) and VEGFR-targeted therapies: A single-institution experience by Wiele, A.J., Ross, J., Chahoud, J., Lim, Z., Xiao, L., Campbell, M.T., Shah, A.Y., Zurita Saavedra, A., Jonasch, E., Tannir, N.M.

“…ICI and VEGFR-targeted therapies are the primary treatments for mRCC. Len plus Eve is currently approved based on improved progression-free survival (PFS) in…”
Get full text